These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25733301)

  • 1. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma.
    Faraj SF; Munari E; Guner G; Taube J; Anders R; Hicks J; Meeker A; Schoenberg M; Bivalacqua T; Drake C; Netto GJ
    Urology; 2015 Mar; 85(3):703.e1-6. PubMed ID: 25733301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
    Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
    Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features.
    Bai Y; Wu X; Weng M; Han Q; Xu L; Chang C; Teng X
    Indian J Pathol Microbiol; 2023; 66(4):702-707. PubMed ID: 38084519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.
    Donizy P; Wu CL; Kopczynski J; Pieniazek M; Biecek P; Ryś J; Hoang MP
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC.
    Kossaï M; Radulescu C; Adam J; Dziegielewski A; Signolle N; Sibony M; Lebret T; Allory Y; Rouanne M
    Urol Oncol; 2022 Jan; 40(1):12.e1-12.e11. PubMed ID: 34429252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples.
    Möller K; Knöll M; Bady E; Schmerder MJ; Rico SD; Kluth M; Hube-Magg C; Blessin NC; Mandelkow T; Lennartz M; Menz A; Luebke AM; Höflmayer D; Fraune C; Bernreuther C; Lebok P; Uhlig R; Contreras H; Weidemann S; Gorbokon N; Jacobsen F; Clauditz TS; Steurer S; Burandt E; Minner S; Sauter G; Simon R; Marx AH; Krech T
    Cancer Biomark; 2023; 36(2):177-191. PubMed ID: 36683495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors.
    Plage H; Furlano K; Hofbauer S; Weinberger S; Ralla B; Franz A; Fendler A; de Martino M; Roßner F; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Zecha H; Minner S; Simon R; Sauter G; Weischenfeldt J; Klatte T; Schlomm T; Horst D; Schallenberg S
    BMC Urol; 2024 Apr; 24(1):96. PubMed ID: 38658905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
    Holland BC; Sood A; Delfino K; Dynda DI; Ran S; Freed N; Alanee S
    Cancer Immunol Immunother; 2019 Jun; 68(6):991-997. PubMed ID: 30997535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
    Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
    Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
    Gulinac M; Dikov D; Velikova T; Belovezhdov V
    Ann Diagn Pathol; 2020 Dec; 49():151640. PubMed ID: 33069081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.
    Krabbe LM; Heitplatz B; Preuss S; Hutchinson RC; Woldu SL; Singla N; Boegemann M; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Rapoport LM; Glybochko PV; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Xylinas E; Margulis V
    J Urol; 2017 Dec; 198(6):1253-1262. PubMed ID: 28668287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal-subtype bladder tumours show a 'hot' immunophenotype.
    Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
    Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
    Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.
    Zhu J; Wen H; Ju X; Bi R; Zuo W; Wu X
    PLoS One; 2017; 12(1):e0170879. PubMed ID: 28125702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.